Role of Prohepcidin in Uremic Patients
The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.
Chronic Kidney Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||The Relationship of Prohepcidin Levels With Anemia and Inflammatory Markers in Non-diabetic Uremic Patients: A Controlled Study|
- prohepcidin level [ Time Frame: Six months ] [ Designated as safety issue: No ]Prohepcidin levels will be compared with other inflammatory markers.
- Anemia and inflammatory markers [ Time Frame: Six months ] [ Designated as safety issue: No ]Correlations of prohepcidin levels with anemia and inflamatory markers
|Study Start Date:||January 2010|
|Study Completion Date:||March 2011|
|Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
Patients on chronic hemodialysis program
Peritoneal dialysis group
Patients on chronic peritoneal dialysis program
Patients with chronic kidney disease stage-4